UMIN-CTR Clinical Trial

Basic information
Public title	Safety Evaluation of Long-Term Intake of a Test Food Containing Plant Extract
Acronym	Safety Evaluation of Long-Term Intake of a Test Food Containing Plant Extract
Scientific Title	Safety Evaluation of Long-Term Intake of a Test Food Containing Plant Extract
Scientific Title:Acronym	Safety Evaluation of Long-Term Intake of a Test Food Containing Plant Extract
Region	Japan

Condition
Condition	N/A(healthy adults)
Classification by specialty	Adult
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	This study examines safety of long-term intake (12 weeks) of a test food containing plant extract.
Basic objectives2	Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	[1]Existence and its contents of side effects: number of cases and expression rate of side effects (expression rate: number of cases/number of cases analyzed) (SCR, Week 0, Week 4, Week 8, Week 12)
Key secondary outcomes	*Secondary outcomes [1]Adverse events: number of cases and expression rate of adverse events (expression rate: number of cases/number of cases analyzed) (SCR, Week 0, Week 4, Week 8, Week 12) [2]Blood pressure, pulsation (SCR, Week 0, Week 4, Week 8, Week 12) [3]Weight, body fat percentage, BMI (SCR, Week 0, Week 4, Week 8, Week 12) [4]Hematologic test (SCR, Week 0, Week 4, Week 8, Week 12) [5]Blood biochemical test (SCR, Week 0, Week 4, Week 8, Week 12) [6]Urine analysis (SCR, Week 0, Week 4, Week 8, Week 12) [7]Doctor's questions (SCR, Week 0, Week 4, Week 8, Week 12) *Other index [1]Subject's diary (each day during the test period)

Base
Study type	Interventional

Study design
Basic design	Parallel
Randomization	Randomized
Randomization unit	Individual
Blinding	Double blind -all involved are blinded
Control	Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms	2
Purpose of intervention	Treatment
Type of intervention	Other
Interventions/Control_1	Oral intake of the test product (containing plant extract; 100mL in a day for 12 weeks)
Interventions/Control_2	Oral intake of the placebo product (not containing plant extract; 100mL in a day for 12 weeks)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	20 years-old <=
Age-upper limit	65 years-old >=
Gender	Male and Female
Key inclusion criteria	[1]Japanese males and females aged 20-65 years (estimated male-female rate of subjects is 1:1; the generation variability of subjects shall be avoided). [2]Individuals whose BMI is over 18.5 and under 30. [3]Individuals who are healthy and are not suffered from a chronic malady. [4]Individuals whose written informed consent has been obtained. [5]Individuals who can come to the designated venue for this study and be inspected. [6]Individuals judged appropriate for the study by the principal.
Key exclusion criteria	[1]Individuals using medical products. [2]Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. [3]Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis). [4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease. [5]Individuals who are a patient or have a history of or endocrine disease. [6]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months. [7]Individuals who experienced unpleasant feeling during blood drawing. [8]Individuals who are sensitive to a test product or other foods, and medical products. [9]Individuals who habitually take the foods for specified health uses (FOSHU) or functional food. (Except for subjects who can stop consume them after informed consent). [10]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day). [11]Individuals with possible changes of life style, such as conducting a long-term travel, during the test period. [12]Individuals who are or are possibly, or are lactating. [13]Individuals who participated in other clinical studies in the past 3 months. [14]Individuals who are or whose family is engaged in healthy or functional foods. [15]Individuals judged inappropriate for the study by the principal.
Target sample size	40

Research contact person
Name of lead principal investigator	1st name Middle name Last name Toshifumi Okusa
Organization	Oriental Ueno Detection Center, General Incorporated Association Oriental Occupational Health Association Tokyo Branch
Division name	Head of center
Zip code
Address	1-20-11 Ueno Taito-ku Tokyo 110-0005, JAPAN
TEL	+81-3-5816-0711
Email	info@tes-h.co.jp

Public contact
Name of contact person	1st name Middle name Last name Ryoma Shimizu
Organization	TES Holdings Co., Ltd
Division name	Administrative Department of Clinical Trials
Zip code
Address	6F University of Tokyo Entrepreneur Plaza 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, JAPAN
TEL	+81-3-6801-8480
Homepage URL
Email	r.shimizu@tes-h.co.jp

Sponsor
Institute	TES Holdings Co., Ltd
Institute
Department

Funding Source
Organization	Ogawa & Co., Ltd
Organization
Division
Category of Funding Organization	Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2017 Year 07 Month 21 Day

Related information
URL releasing protocol
Publication of results	Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status	Completed
Date of protocol fixation	2017 Year 07 Month 07 Day
Date of IRB
Anticipated trial start date	2017 Year 07 Month 30 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date	2017 Year 07 Month 21 Day
Last modified on	2017 Year 12 Month 14 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032314

Research Plan
Registered date	File name

Research case data specifications
Registered date	File name

Research case data
Registered date	File name

Contact us.